Granisetron.
Granisetron is the second agent in the 5-HT3 receptor antagonist class to be approved for the prophylaxis of acute emesis caused by cancer chemotherapy. It is equally effective to ondansetron as a first-line agent in the prevention of acute chemotherapy-induced emesis and has a similar low toxicity profile. Granisetron will be marketed in early 1994, according to SmithKline Beecham. Additional studies will be needed to determine the role of granisetron in the current management of chemotherapy-induced emesis.
Ignoffo
R J
RJ
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D017829:Granisetron / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000970:Antineoplastic Agents; D017829:Granisetron